Showing results (11-20 of 689) with videos related to
Sort By:
Pageof 69
Cardiovascular Diabetology|September 1, 2022
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reductionMichael A Nauck, David A D'AlessioThe Lancet. Diabetes & Endocrinology|February 16, 2016
The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventionsMichael A Nauck, Juris J MeierFrontiers in Endocrinology|April 15, 2021
Cardiovascular Safety and Benefits of Semaglutide in Patients With Type 2 Diabetes: Findings From SUSTAIN 6 and PIONEER 6Michael A Nauck, Daniel R QuastBest Practice & Research. Clinical Endocrinology & Metabolism|November 10, 2004
Clinical endocrinology and metabolism. Glucose-dependent insulinotropic polypeptide/gastric inhibitory polypeptideJuris J Meier, Michael A NauckAnnals of Internal Medicine|December 5, 2012
Diagnostic accuracy of an "amended" insulin-glucose ratio for the biochemical diagnosis of insulinomasMichael A Nauck, Juris J MeierEuropean Journal of Endocrinology|October 11, 2019
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?Michael A Nauck, Juris J MeierDiabetologia|April 12, 2014
Risk of pancreatitis in patients treated with incretin-based therapiesJuris J Meier, Michael A NauckRegulatory Peptides|March 23, 2005
Glucagon-like peptide 1 and its derivatives in the treatment of diabetesMichael A Nauck, Juris J MeierDiabetes/Metabolism Research and Reviews|March 11, 2005
Glucagon-like peptide 1(GLP-1) in biology and pathologyJuris J Meier, Michael A NauckPageof 69